CF Foundation gives $9M more to advance mRNA therapy in testing
The Cystic Fibrosis (CF) Foundation is giving up to $9 million in additional support to advance clinical testing of ARCT-032, a messenger RNA therapy with the potential to benefit anyone with CF, regardless of their disease-causing mutation. Arcturus Therapeutics, the inhalation therapy’s developer, is using the funding…